In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents

Hui Pang, Guilian Li, Li Wan, Yi Jiang, Haican Liu, Xiuqin Zhao, Z. Zhao, Kanglin Wan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rapidly growing mycobacteria (RGM) are human pathogens that are relatively easily identified by acid-fast staining but are proving difficult to treat in the clinic. In this study, we performed susceptibility testing of 40 international reference RGM species against 20 antimicrobial agents using the cation-adjusted Mueller-Hinton (CAMH) broth microdilution based on the minimum inhibitory concentration (MIC) assay recommended by the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The results demonstrated that RGM organisms were resistant to the majority of first-line antituberculous agents but not to second-line fluoroquinolones or aminoglycosides. Three drugs (amikacin, tigecycline and linezolid) displayed potent antimycobacterial activity against all tested strains. Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. Mycobacterium chelonae (M. chelonae), M. abscessus, M. bolletii, M. fortuitum, M. boenickei, M. conceptionense, M. pseudoshottsii, M. septicum and M. setense were the most resistant RGM species. These results provide significant insight into the treatment of RGM species and will assist optimization of clinical criteria.

Original languageEnglish
Pages (from-to)15423-15431
Number of pages9
JournalInternational Journal of Clinical and Experimental Medicine
Volume8
Issue number9
Publication statusPublished - Sep 30 2015

Fingerprint

Linezolid
meropenem
Mycobacterium
Anti-Infective Agents
Capreomycin
Cefoxitin
Levofloxacin
Amikacin
Fluoroquinolones
Aminoglycosides
Pathogens
Pharmaceutical Preparations
Cations
Assays
Acids
Mycobacterium chelonae
Testing
Mycobacterium Infections
Microbial Sensitivity Tests
In Vitro Techniques

Keywords

  • Antimicrobial
  • Drug susceptibility
  • Minimum inhibitory concentration (MIC)
  • Rapidly growing mycobacteria (RGM)
  • Reference strains

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents. / Pang, Hui; Li, Guilian; Wan, Li; Jiang, Yi; Liu, Haican; Zhao, Xiuqin; Zhao, Z.; Wan, Kanglin.

In: International Journal of Clinical and Experimental Medicine, Vol. 8, No. 9, 30.09.2015, p. 15423-15431.

Research output: Contribution to journalArticle

Pang, Hui ; Li, Guilian ; Wan, Li ; Jiang, Yi ; Liu, Haican ; Zhao, Xiuqin ; Zhao, Z. ; Wan, Kanglin. / In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents. In: International Journal of Clinical and Experimental Medicine. 2015 ; Vol. 8, No. 9. pp. 15423-15431.
@article{d1b1e22f68054d9fb8a3cd5c00806e5b,
title = "In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents",
abstract = "Rapidly growing mycobacteria (RGM) are human pathogens that are relatively easily identified by acid-fast staining but are proving difficult to treat in the clinic. In this study, we performed susceptibility testing of 40 international reference RGM species against 20 antimicrobial agents using the cation-adjusted Mueller-Hinton (CAMH) broth microdilution based on the minimum inhibitory concentration (MIC) assay recommended by the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The results demonstrated that RGM organisms were resistant to the majority of first-line antituberculous agents but not to second-line fluoroquinolones or aminoglycosides. Three drugs (amikacin, tigecycline and linezolid) displayed potent antimycobacterial activity against all tested strains. Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. Mycobacterium chelonae (M. chelonae), M. abscessus, M. bolletii, M. fortuitum, M. boenickei, M. conceptionense, M. pseudoshottsii, M. septicum and M. setense were the most resistant RGM species. These results provide significant insight into the treatment of RGM species and will assist optimization of clinical criteria.",
keywords = "Antimicrobial, Drug susceptibility, Minimum inhibitory concentration (MIC), Rapidly growing mycobacteria (RGM), Reference strains",
author = "Hui Pang and Guilian Li and Li Wan and Yi Jiang and Haican Liu and Xiuqin Zhao and Z. Zhao and Kanglin Wan",
year = "2015",
month = "9",
day = "30",
language = "English",
volume = "8",
pages = "15423--15431",
journal = "International Journal of Clinical and Experimental Medicine",
issn = "1940-5901",
publisher = "e-Century Publishing Corporation",
number = "9",

}

TY - JOUR

T1 - In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents

AU - Pang, Hui

AU - Li, Guilian

AU - Wan, Li

AU - Jiang, Yi

AU - Liu, Haican

AU - Zhao, Xiuqin

AU - Zhao, Z.

AU - Wan, Kanglin

PY - 2015/9/30

Y1 - 2015/9/30

N2 - Rapidly growing mycobacteria (RGM) are human pathogens that are relatively easily identified by acid-fast staining but are proving difficult to treat in the clinic. In this study, we performed susceptibility testing of 40 international reference RGM species against 20 antimicrobial agents using the cation-adjusted Mueller-Hinton (CAMH) broth microdilution based on the minimum inhibitory concentration (MIC) assay recommended by the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The results demonstrated that RGM organisms were resistant to the majority of first-line antituberculous agents but not to second-line fluoroquinolones or aminoglycosides. Three drugs (amikacin, tigecycline and linezolid) displayed potent antimycobacterial activity against all tested strains. Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. Mycobacterium chelonae (M. chelonae), M. abscessus, M. bolletii, M. fortuitum, M. boenickei, M. conceptionense, M. pseudoshottsii, M. septicum and M. setense were the most resistant RGM species. These results provide significant insight into the treatment of RGM species and will assist optimization of clinical criteria.

AB - Rapidly growing mycobacteria (RGM) are human pathogens that are relatively easily identified by acid-fast staining but are proving difficult to treat in the clinic. In this study, we performed susceptibility testing of 40 international reference RGM species against 20 antimicrobial agents using the cation-adjusted Mueller-Hinton (CAMH) broth microdilution based on the minimum inhibitory concentration (MIC) assay recommended by the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The results demonstrated that RGM organisms were resistant to the majority of first-line antituberculous agents but not to second-line fluoroquinolones or aminoglycosides. Three drugs (amikacin, tigecycline and linezolid) displayed potent antimycobacterial activity against all tested strains. Capreomycin, levofloxacin and moxifloxacin emerged as promising candidates for the treatment of RGM infections, and cefoxitin and meropenem were active against most strains. Mycobacterium chelonae (M. chelonae), M. abscessus, M. bolletii, M. fortuitum, M. boenickei, M. conceptionense, M. pseudoshottsii, M. septicum and M. setense were the most resistant RGM species. These results provide significant insight into the treatment of RGM species and will assist optimization of clinical criteria.

KW - Antimicrobial

KW - Drug susceptibility

KW - Minimum inhibitory concentration (MIC)

KW - Rapidly growing mycobacteria (RGM)

KW - Reference strains

UR - http://www.scopus.com/inward/record.url?scp=84946600936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946600936&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 15423

EP - 15431

JO - International Journal of Clinical and Experimental Medicine

JF - International Journal of Clinical and Experimental Medicine

SN - 1940-5901

IS - 9

ER -